Why NeoGenomics (NEO) Stock Is Up Today
NeoGenomics (NEO) shares rose 15.8% after the company reported Q2 2026 adjusted EPS of $0.05 on revenue of $201.7 million, beating Wall Street forecasts of $0.03 and $197.3 million. NeoGenomics also raised full-year guidance to about $804 million revenue and $0.19 adjusted EPS.
How this was made
The 30-second read
Why it matters
The immediate driver is the Q2 earnings beat and the full-year guidance raise, which can trigger estimate upgrades and multiple expansion for the stock in the near term.
Market read
Traders can treat this as a guidance-driven repricing event for NEO, with potential for continued momentum if analysts follow up with upgrades.
What to watch
The piece does not address cash flow, gross margin trends, competitive dynamics, or whether the guidance raise reflects sustainable demand versus timing effects.
Background
NeoGenomics is an oncology diagnostics company; the article also references a prior FDA-approved IHC companion diagnostic launch (PTEN IHC CDx) tied to patient eligibility for AstraZeneca’s TRUQAP.
Ticker impact
NeoGenomics shares jumped 15.8% after Q2 2026 adjusted EPS of $0.05 beat estimates and the company raised full-year revenue guidance to about $804M.
Bullish bias for the next several sessions as traders reprice FY revenue and EPS expectations; follow-through depends on whether guidance is sustained in subsequent quarters.
The article cites specific Q2 results versus consensus and provides updated full-year revenue and adjusted EPS guidance, which typically drives immediate repricing and analyst model updates.
Market effects
Positive read-through for oncology diagnostics sentiment, especially for companies tied to companion diagnostics and treatment eligibility workflows.
Primarily US small/mid-cap biotech/diagnostics sentiment; limited direct regional spillover described.
No explicit global catalyst beyond the US-listed company’s guidance and FDA-linked product context.
Counterpoint
A large one-day move can fade if the raised guidance is still modest versus the market’s longer-term expectations or if margins/quality of earnings are questioned (not discussed in the article).
Key entities
- companyNeoGenomics
Oncology diagnostics company whose Q2 2026 earnings beat and raised FY guidance drove a large share move.
- companyAstraZeneca
Referenced for its TRUQAP targeted therapy, which depends on diagnostic eligibility linked to NeoGenomics’ companion test.
